Novo FLOW trial results positive for Outset Medical, says RBC Capital

After Novo Nordisk (NVO) announced that the kidney outcomes trial FLOW demonstrated a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events, or MACE, and death of 24%, RBC Capital said the results, while “encouraging,” are shy of the at least 30% expectation. The FLOW trial is the only ongoing designated kidney outcome trial with a GLP-1s and these results make it unclear how much of a benefit GLP-1s will provide in addition to SGLT2 inhibitors, says the firm, which calls the FLOW results positive for Outset Medical (OM). The firm maintains a Sector Perform rating and $5 price target on Outset shares.